Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Share-based Compensation (2016 - 2025)

Guided Therapeutics' Share-based Compensation history spans 15 years, with the latest figure at $22000.0 for Q3 2025.

  • For Q3 2025, Share-based Compensation fell 73.75% year-over-year to $22000.0; the TTM value through Sep 2025 reached $235659.0, up 198.3%, while the annual FY2024 figure was $16659.0, 99.08% down from the prior year.
  • Share-based Compensation for Q3 2025 was $22000.0 at Guided Therapeutics, down from $329981.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.1 million in Q2 2023 and bottomed at -$116341.0 in Q4 2024.
  • The 5-year median for Share-based Compensation is $56000.0 (2021), against an average of $194982.1.
  • The largest annual shift saw Share-based Compensation skyrocketed 2443.18% in 2023 before it plummeted 115.45% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $50000.0 in 2021, then surged by 668.0% to $384000.0 in 2022, then tumbled by 114.06% to -$54000.0 in 2023, then crashed by 115.45% to -$116341.0 in 2024, then skyrocketed by 118.91% to $22000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Share-based Compensation are $22000.0 (Q3 2025), $329981.0 (Q2 2025), and $19.0 (Q1 2025).